newsUpadacitinib meets all endpoints in Phase III ulcerative colitis trial23 February 2021 | By Hannah Balfour (European Pharmaceutical Review)In the trial, 74 percent of participants responded to upadacitinib and 33 percent of patients achieved clinical remission.